Which has stronger earnings and valuation, INKT or PASG?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A Passage Bio N/A N/A -$45.52M -$11.84 N/A

Is INKT or PASG more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -118.57% Passage Bio N/A -150.88% -59.78%

Do analysts prefer BYSI or PASG?

Passage Bio has a consensus price target of $13.25, indicating a potential upside of 175.18%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11

Is BYSI or PASG more profitable?

BeyondSpring's return on equity of 0.00% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Passage Bio N/A -150.88% -59.78%

Do analysts recommend INMB or PASG?

Passage Bio has a consensus target price of $13.25, indicating a potential upside of 175.18%. Given Passage Bio's higher probable upside, analysts plainly believe Passage Bio is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11

Is INMB or PASG more profitable?

INmune Bio's return on equity of -103.03% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% Passage Bio N/A -150.88% -59.78%

Do analysts recommend INCR or PASG?

Passage Bio has a consensus target price of $13.25, suggesting a potential upside of 175.18%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11

Which has better earnings and valuation, INCR or PASG?

InterCure has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InterCure $78.47M 0.63 -$10.37M $0.03 29.97 Passage Bio N/A N/A -$45.52M -$11.84 N/A

Is INCR or PASG more profitable?

InterCure's return on equity of 0.00% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Passage Bio N/A -150.88% -59.78%

Which has stronger earnings and valuation, PASG or FLNA?

Cassava Sciences is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is PASG or FLNA more profitable?

Cassava Sciences' return on equity of -53.90% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% Cassava Sciences N/A -53.90% -34.20%

Passage Bio (PASG) Competitors

$4.82 +0.01 (+0.10%)

As of 10:31 AM Eastern

Compare

PASG vs. INKT, BYSI, INMB, INCR, and FLNA

Should you buy Passage Bio stock or one of its competitors? MarketBeat compares Passage Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Passage Bio include MiNK Therapeutics (INKT), BeyondSpring (BYSI), INmune Bio (INMB), InterCure (INCR), and Cassava Sciences (FLNA). These companies are all part of the "pharmaceutical products" industry.

How does Passage Bio compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

In the previous week, MiNK Therapeutics had 2 more articles in the media than Passage Bio. MarketBeat recorded 2 mentions for MiNK Therapeutics and 0 mentions for Passage Bio. MiNK Therapeutics' average media sentiment score of 1.20 beat Passage Bio's score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MiNK Therapeutics	Positive
Passage Bio	Neutral

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by company insiders. Comparatively, 4.9% of Passage Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

MiNK Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 215.71%. Passage Bio has a consensus target price of $13.25, indicating a potential upside of 175.18%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MiNK Therapeutics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

MiNK Therapeutics' return on equity of 0.00% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Passage Bio	N/A	-150.88%	-59.78%

MiNK Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

Summary

MiNK Therapeutics beats Passage Bio on 9 of the 14 factors compared between the two stocks.

How does Passage Bio compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

BeyondSpring's return on equity of 0.00% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Passage Bio	N/A	-150.88%	-59.78%

BeyondSpring has higher revenue and earnings than Passage Bio. BeyondSpring is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	30.10	-$1.01M	-$0.14	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 29.3% of BeyondSpring shares are held by company insiders. Comparatively, 4.9% of Passage Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, BeyondSpring's average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score.

Company	Overall Sentiment
BeyondSpring	Neutral
Passage Bio	Neutral

Passage Bio has a consensus price target of $13.25, indicating a potential upside of 175.18%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

BeyondSpring has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

Summary

BeyondSpring and Passage Bio tied by winning 6 of the 12 factors compared between the two stocks.

How does Passage Bio compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Passage Bio has a consensus target price of $13.25, indicating a potential upside of 175.18%. Given Passage Bio's higher probable upside, analysts plainly believe Passage Bio is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 21.4% of INmune Bio shares are held by insiders. Comparatively, 4.9% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, INmune Bio had 3 more articles in the media than Passage Bio. MarketBeat recorded 3 mentions for INmune Bio and 0 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.00 beat INmune Bio's score of -0.61 indicating that Passage Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
INmune Bio	Negative
Passage Bio	Neutral

INmune Bio's return on equity of -103.03% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Passage Bio	N/A	-150.88%	-59.78%

Passage Bio has lower revenue, but higher earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,049.91	-$45.93M	-$1.67	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

INmune Bio has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

Summary

Passage Bio beats INmune Bio on 8 of the 15 factors compared between the two stocks.

How does Passage Bio compare to InterCure?

InterCure (NASDAQ:INCR) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

InterCure's return on equity of 0.00% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Passage Bio	N/A	-150.88%	-59.78%

InterCure has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Passage Bio has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

8.3% of InterCure shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 4.9% of Passage Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

InterCure has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.63	-$10.37M	$0.03	29.97
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

In the previous week, InterCure's average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score.

Company	Overall Sentiment
InterCure	Neutral
Passage Bio	Neutral

Passage Bio has a consensus target price of $13.25, suggesting a potential upside of 175.18%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

Summary

InterCure and Passage Bio tied by winning 6 of the 12 factors compared between the two stocks.

How does Passage Bio compare to Cassava Sciences?

Passage Bio (NASDAQ:PASG) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Cassava Sciences is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Passage Bio has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, suggesting that its share price is 173% less volatile than the broader market.

In the previous week, Cassava Sciences had 2 more articles in the media than Passage Bio. MarketBeat recorded 2 mentions for Cassava Sciences and 0 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score.

Company	Overall Sentiment
Passage Bio	Neutral
Cassava Sciences	Neutral

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Passage Bio presently has a consensus target price of $13.25, indicating a potential upside of 175.18%. Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 386.19%. Given Cassava Sciences' higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cassava Sciences' return on equity of -53.90% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Cassava Sciences	N/A	-53.90%	-34.20%

Summary

Passage Bio beats Cassava Sciences on 7 of the 12 factors compared between the two stocks.

Get Passage Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PASG vs. The Competition

Export

Metric	Passage Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.46M	$3.64B	$6.80B	$12.37B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.41	20.71	27.09	24.07
Price / Sales	N/A	302.58	520.26	91.86
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.82	7.99	10.64	6.20
Net Income	-$45.52M	$23.81M	$3.60B	$331.63M
7 Day Performance	8.45%	-1.92%	-1.41%	-1.54%
1 Month Performance	-13.86%	1.88%	0.97%	-1.17%
1 Year Performance	-8.63%	43.58%	24.23%	17.81%

Passage Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PASG Passage Bio	3.2516 of 5 stars	$4.82 +0.1%	$13.25 +175.2%	-13.5%	$15.46M	N/A	N/A	130
INKT MiNK Therapeutics	3.0637 of 5 stars	$11.31 +1.4%	$35.00 +209.6%	-47.0%	$56.30M	N/A	N/A	30	Positive News Gap Down
BYSI BeyondSpring	0.0306 of 5 stars	$1.35 +1.2%	N/A	-43.1%	$55.51M	$1.75M	N/A	80	Gap Down
INMB INmune Bio	0.8085 of 5 stars	$2.04 +9.5%	N/A	-17.8%	$54.09M	$50K	N/A	10
INCR InterCure	0.9339 of 5 stars	$0.98 +3.6%	N/A	-40.1%	$53.81M	$78.47M	32.80	350	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PASG) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Passage Bio (PASG) Competitors

PASG vs. INKT, BYSI, INMB, INCR, and FLNA

How does Passage Bio compare to MiNK Therapeutics?

Summary

How does Passage Bio compare to BeyondSpring?

Summary

How does Passage Bio compare to INmune Bio?

Summary

How does Passage Bio compare to InterCure?

Summary

How does Passage Bio compare to Cassava Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Passage Bio (PASG) Competitors

PASG vs. INKT, BYSI, INMB, INCR, and FLNA

How does Passage Bio compare to MiNK Therapeutics?

Which has stronger earnings and valuation, INKT or PASG?

Does the media prefer INKT or PASG?

Do insiders & institutionals hold more shares of INKT or PASG?

Do analysts recommend INKT or PASG?

Is INKT or PASG more profitable?

Which has more risk & volatility, INKT or PASG?

Summary

How does Passage Bio compare to BeyondSpring?

Is BYSI or PASG more profitable?

Which has stronger valuation & earnings, BYSI or PASG?

Do institutionals & insiders believe in BYSI or PASG?

Does the media prefer BYSI or PASG?

Do analysts prefer BYSI or PASG?

Which has more risk and volatility, BYSI or PASG?

Summary

How does Passage Bio compare to INmune Bio?

Do analysts recommend INMB or PASG?

Do institutionals and insiders believe in INMB or PASG?

Does the media refer more to INMB or PASG?

Is INMB or PASG more profitable?

Which has stronger earnings & valuation, INMB or PASG?

Which has more risk and volatility, INMB or PASG?

Summary

How does Passage Bio compare to InterCure?

Is INCR or PASG more profitable?

Which has more risk & volatility, INCR or PASG?

Do insiders & institutionals believe in INCR or PASG?

Which has better earnings and valuation, INCR or PASG?

Does the media favor INCR or PASG?

Do analysts recommend INCR or PASG?

Summary

How does Passage Bio compare to Cassava Sciences?

Which has stronger earnings and valuation, PASG or FLNA?

Which has more volatility & risk, PASG or FLNA?

Does the media prefer PASG or FLNA?

Do institutionals & insiders believe in PASG or FLNA?

Do analysts rate PASG or FLNA?

Is PASG or FLNA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools